Dr. Falk Pharma GmbH

Based in Freiburg, Germany, Dr. Falk Pharma develops treatments for gastrointestinal and liver disorders, including inflammatory bowel disease, eosinophilic esophagitis, and primary biliary cholangitis. In October 2024, Dr. Falk Pharma GmbH acquired Kynos Therapeutics Ltd.

from Epidarex Capital, IP Group, and Scottish Enterprise. Dr. Falk Pharma specializes in the development and distribution of medicines primarily aimed at improving patient health in the fields of digestive and metabolic medicine. Their core product offerings include therapies for various conditions such as inflammatory bowel disease (IBD), autoimmune hepatitis, and primary biliary cholangitis.

The company targets end users such as patients suffering from these chronic conditions, as well as healthcare professionals who require effective treatment options for their patients. Dr. Falk Pharma’s products are available in multiple international markets, including Germany, the United Kingdom, France, and Australia, reflecting a broad global reach. Dr.

Falk Pharma’s revenue streams are derived from the sale of its proprietary medications and therapies through various channels, including direct sales to healthcare providers and partnerships with distributors and pharmacies. The company operates on a business-to-business model, primarily engaging with hospitals, clinics, and healthcare practitioners who prescribe their products to patients. Transactions occur as healthcare providers order medications based on patient needs, ensuring a direct flow of products to end users.